XML 26 R8.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Dec. 30, 2023
Cash flows from operating activities:      
Net income $ 54,361 $ 69,614 $ 82,387
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 37,589 32,903 37,453
Accretion of discount on investments (1,975) (3,240) (2,828)
Reduction in the carrying amount of right-of-use assets 6,880 6,803 7,389
Stock-based compensation expense 38,576 39,763 38,616
Deferred income tax provision (benefit) 1,927 (13,355) (12,100)
Gain on sale of business (103) (20,581) (72,953)
Provision for excess and obsolete inventories 14,853 12,342 15,003
Acquired inventory step-up amortization 0 0 501
Non-cash restructuring charges 2,119 428 0
Foreign currency transaction losses 2,110 1,509 2,282
Other than temporary impairment on debt receivable 0 0 1,083
Changes in assets and liabilities:      
Accounts receivable (20,156) (1,921) (23,304)
Inventories (20,663) (8,259) (9,488)
Prepaid expenses and other current assets 734 546 (3,057)
Other assets (483) 285 (146)
Accounts payable (5,682) (8,235) 1,319
Accrued liabilities 4,601 3,675 (2,424)
Other liabilities 2,258 9,834 4,660
Deferred revenues 4,489 2,699 (10,176)
Deferred grant 0 0 18,000
Operating lease liabilities (8,063) (7,276) (7,615)
Net cash provided by operating activities 115,398 117,534 64,602
Cash flows from investing activities:      
Acquisition of property, plant and equipment (103,658) (38,436) (56,027)
Acquisition of business, net of cash acquired (20,580) 0 0
Proceeds from sale of business and assets 103 21,585 101,785
Purchase of promissory note receivable 0 (1,500) 0
Purchases of marketable securities (126,307) (139,091) (135,462)
Proceeds from maturities and sales of marketable securities 126,130 123,962 118,753
Net cash provided by (used in) investing activities (191,468) (33,480) 29,049
Cash flows from financing activities:      
Proceeds from issuances of common stock 26,119 9,748 8,822
Purchase of common stock through stock repurchase program, including excise tax paid (26,244) (53,302) (19,801)
Tax withholdings related to net share settlements of equity awards (12,402) (19,983) (10,687)
Payments on term loan (1,106) (1,075) (1,045)
Net cash used in financing activities (13,633) (64,612) (22,711)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (456) (3,509) (2,649)
Net increase (decrease) in cash, cash equivalents and restricted cash (90,159) 15,933 68,291
Cash, cash equivalents and restricted cash, beginning of year 197,206 181,273 112,982
Cash, cash equivalents and restricted cash, end of year 107,047 197,206 181,273
Supplemental disclosure of non-cash investing and financing activities:      
Operating lease, right-of-use assets obtained in exchange for lease obligations 954 61 6,491
Increase (decrease) in accounts payable and accrued liabilities related to property, plant and equipment purchases (11,447) 7,194 (5,961)
Supplemental disclosure of cash flow information:      
Cash paid for income taxes, net 8,932 15,584 17,385
Cash paid for interest 362 391 422
Operating cash outflows from operating leases 9,753 9,308 9,135
Reconciliation of cash, cash equivalents and restricted cash:      
Cash and cash equivalents 103,330 190,728 177,812
Restricted cash, current 1,063 3,746 1,152
Restricted cash 2,654 2,732 2,309
Total cash, cash equivalents and restricted cash 107,047 197,206 181,273
Income (Loss) from Equity Method Investments 2,026 0 0
Payments to Acquire Equity Method Investments $ (67,156) $ 0 $ 0